Stock Events

Stock Events

Editas Medicine 

$2.44
262
-$0.1-3.94% Friday 20:00

Statistics

Day High
2.64
Day Low
2.42
52W High
4.54
52W Low
0.91
Volume
1,196,794
Avg. Volume
1,858,025
Mkt Cap
238.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.92
-0.63
-0.35
-0.06
Expected EPS
-0.27125
Actual EPS
N/A

Financials

-733.72%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
64.63MRevenue
-474.19MNet Income

Analyst Ratings

$5.75Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EDIT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is directly competing in the CRISPR/Cas9 gene-editing space, focusing on developing transformative gene-based medicines for serious diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading competitor in the development of in vivo gene editing treatments using CRISPR/Cas9 technology, similar to Editas' approach.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing, a newer form of gene editing technology that competes with CRISPR/Cas9 methods employed by Editas for precise and reduced-risk gene editing.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics competes with Editas in the broader gene editing market, focusing on zinc finger nuclease (ZFN) technology, an alternative to CRISPR/Cas9.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals competes in the RNAi therapeutic space, offering a different approach to gene therapy that could rival Editas' gene editing technologies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals collaborates with CRISPR Therapeutics on gene editing therapies, indirectly competing with Editas through their joint development efforts in the CRISPR/Cas9 space.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disorder treatments, competing with Editas in the broader market for genetic disease therapies.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics operates in the genetic disorder space, offering treatments that could compete with gene editing therapies developed by Editas.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, presenting a competitive alternative to Editas' gene editing approach.

About

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Show more...
CEO
Dr. Gilmore O'Neill M.D.
Employees
246
Country
US
ISIN
US28106W1036

Listings

LSE
GB
0IFK.LSE
XNAS
US
EDIT
F
DE
8EM.F
BOATS
BOATS
EDIT.BOATS

0 Comments

Share your thoughts

FAQ

What is Editas Medicine stock price today?▼
The current price of EDIT is $2.44 USD — it has decreased by -3.94% in the past 24 hours. Watch Editas Medicine stock price performance more closely on the chart.
What is Editas Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Editas Medicine stocks are traded under the ticker EDIT.
Is Editas Medicine stock price growing?▼
EDIT stock has risen by +22% compared to the previous week, the month change is a +38.64% rise, over the last year Editas Medicine has showed a +67.12% increase.
What is Editas Medicine market cap?▼
Today Editas Medicine has the market capitalization of 238.19M
When is the next Editas Medicine earnings date?▼
Editas Medicine is going to release the next earnings report on May 06, 2026.
What were Editas Medicine earnings last quarter?▼
EDIT earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.23 USD resulting in a +74.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Editas Medicine revenue for the last year?▼
Editas Medicine revenue for the last year amounts to 64.63M USD.
What is Editas Medicine net income for the last year?▼
EDIT net income for the last year is -474.19M USD.
How many employees does Editas Medicine have?▼
As of March 15, 2026, the company has 246 employees.
In which sector is Editas Medicine located?▼
Editas Medicine operates in the Health Care sector.
When did Editas Medicine complete a stock split?▼
Editas Medicine has not had any recent stock splits.
Where is Editas Medicine headquartered?▼
Editas Medicine is headquartered in Cambridge, US.